InflaRx gains on FDA's emergency use authorization for COVID injection

Inflarx NV

05/04/2023 10:44

**  U.S.-listed shares of Germany-based biopharma company
InflaRx NV  IFOG.F ,  IFRX.O  rise 11.4% at $4.2 before the bell
    ** U.S. FDA grants emergency-use authorization to co's
monoclonal antibody, Vilobelimab, to treat critically ill
COVID-19 patients when initiated within 48 hours of receiving
artificial life support
    ** Vilobelimab, also known as Gohibic, controls a protein
that plays an important and often harmful role in the body's
immune response
    ** IFRX continues talks with FDA to discuss next step
towards submitting application for full approval
    ** Co's U.S.-listed stock up 21.6% YTD, as of last close  

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))